Obliterans (TAO) continues to be an important cause of limb loss and morbidity in our population.
obliterans and endothelial function.
Wu et al., "High-mobility-group box protein 1 A box reduces development of sodium laurate-induced thromboangiitis
obliterans in rats," Journal of Vascular Surgery, vol.
He had no history of systemic disease other than thromboangiitis
obliterans (TAO) diagnosed for thirty-two years.
All the CLI patients screened had an underlying aetiology due to atherosclerotic arterial occlusive disease (PAD) or Thromboangiitis
Obliterans (TAO)/ Buerger's disease.
(Maodongqing in Chinese) is well known for its roots, which are used as a traditional Chinese medicine for the treatment of cardiovascular diseases such as coronary arterial thrombosis [9,10], heart failure , stroke , and thromboangiitis
obliterans  for a long time.
Buerger's disease, also known as thromboangiitis
obliterans, is a rare condition that inflames the arteries and the veins in the arms and legs.
Buerger's disease, also called thromboangiitis
obliterans, is a recurrent and an uncommon vaso-occlusive inflammatory disease, which typically affects small and medium-sized arteries, veins and nerves of the upper and lower extremities.
He was previously treated as presumed thromboangiitis
obliterans based on the ischemic digit and history of heavy smoking.
BANGALORE, India, June 1, 2015--Stempeutics Research said that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel for the treatment of thromboangiitis
obliterans, a rare and severe disease affecting the blood vessels of the legs.
The company said Stempeucel will be used for the treatment of Thromboangiitis
Obliterans (TAO), a recurring progressive inflammation and thrombosis (clotting) of small and medium arteries and veins of the feet.